Immune Checkpoint Inhibitors in Cancer

Produk Detail:
  • Author : Fumito Ito
  • Publisher : Elsevier Health Sciences
  • Pages : 400 pages
  • ISBN : 0323549500
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Immune Checkpoint Inhibitors in Cancer

Download or Read online Immune Checkpoint Inhibitors in Cancer full in PDF, ePub and kindle. this book written by Fumito Ito and published by Elsevier Health Sciences which was released on 03 September 2018 with total page 400 pages. We cannot guarantee that Immune Checkpoint Inhibitors in Cancer book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. Helps you translate current research and literature into practical information for daily practice. Presents information logically organized by disease site. Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. Consolidates today’s available information on this timely topic into one convenient resource.

Immune Checkpoint Inhibitors in Cancer

Immune Checkpoint Inhibitors in Cancer
  • Author : Fumito Ito,Marc Ernstoff
  • Publisher : Elsevier Health Sciences
  • Release : 03 September 2018
GET THIS BOOK Immune Checkpoint Inhibitors in Cancer

Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Discusses the current understanding of how

Regulation of Cancer Immune Checkpoints

Regulation of Cancer Immune Checkpoints
  • Author : Jie Xu
  • Publisher : Springer Nature
  • Release : 17 March 2020
GET THIS BOOK Regulation of Cancer Immune Checkpoints

This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not

Immune Checkpoint Inhibitors in Non Small Cell Lung Cancer

Immune Checkpoint Inhibitors in Non   Small Cell Lung Cancer
  • Author : Anonim
  • Publisher : Unknown
  • Release : 10 April 2021
GET THIS BOOK Immune Checkpoint Inhibitors in Non Small Cell Lung Cancer

Abstract: Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non‐small cell lung cancer (NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoints have been cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) and the programmed cell death protein‐1 (PD‐1) pathway. In early studies, PD‐1/programmed cell death ligand‐1 (PD‐L1) inhibitors demonstrated promising antitumor activity and durable clinical responses in a subset

Immune Checkpoint Inhibitors for Metastatic Bladder Cancer

Immune Checkpoint Inhibitors for Metastatic Bladder Cancer
  • Author : Anonim
  • Publisher : Unknown
  • Release : 10 April 2021
GET THIS BOOK Immune Checkpoint Inhibitors for Metastatic Bladder Cancer

Highlights: Atezolizumab and Pembrolizumab showed in phase II (Atezolizumab and Pembrolizumab) and phase III (Pembrolizumab) trials to improve clinical outcome of patients progressed to platinum based therapy. Atezolizumab failed to show OS benefit over chemotherapy in a phase III trial for patients progressed to platinum based therapy. Immunotherapy improve clinical outcome of patients unfit to standard first line platinum therapy. We describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors
  • Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum
  • Publisher : National Academies Press
  • Release : 05 October 2019
GET THIS BOOK Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g.,

Immunotherapy

Immunotherapy
  • Author : Aung Naing,Joud Hajjar
  • Publisher : Springer Nature
  • Release : 16 April 2020
GET THIS BOOK Immunotherapy

Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care

Immune Checkpoint Inhibitors in Non small Cell Lung Cancer NSCLC Approaches on Special Subgroups and Unresolved Burning Questions

Immune Checkpoint Inhibitors in Non small Cell Lung Cancer  NSCLC   Approaches on Special Subgroups and Unresolved Burning Questions
  • Author : Anonim
  • Publisher : Unknown
  • Release : 10 April 2021
GET THIS BOOK Immune Checkpoint Inhibitors in Non small Cell Lung Cancer NSCLC Approaches on Special Subgroups and Unresolved Burning Questions

Highlights: ICIs have been incorporated in the treatment strategy of advanced NSCLC. There are still several open questions to be solved such as its efficacy in special subpopulations. Poor PS, brain metastases, autoimmune disorders and retreatment are burning questions. Abstract: Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC). Beyond the already approved indications in first- and second-line setting of advanced NSCLC, new data has recently emerged demonstrating its efficacy in

Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy

Combinatorial Approaches to Enhance Anti Tumor Immunity  Focus on Immune Checkpoint Blockade Therapy
  • Author : Patrik Andersson,Christian Ostheimer
  • Publisher : Frontiers Media SA
  • Release : 27 December 2019
GET THIS BOOK Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy

The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (

Cancer Immunology

Cancer Immunology
  • Author : Nima Rezaei
  • Publisher : Springer Nature
  • Release : 10 April 2021
GET THIS BOOK Cancer Immunology

This translational, clinically oriented book describes in detail novel approaches to cancer immunotherapy, current strategies to target tumor immunosuppression, and prognostic biomarkers for personalized cancer treatments. Since the first, very successful edition of the book was published in 2015, the original chapters have been significantly updated and entirely new chapters are included on, for example, cancer immunoprevention, aptamer-mediated cancer gene therapy, haploidentical bone marrow transplantation for pediatric malignancies, and nanoimmunotherapy. The book is published as part of the three-volume Springer series

Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors
  • Author : Medtech Ventures
  • Publisher : Unknown
  • Release : 18 January 2020
GET THIS BOOK Immune Checkpoint Inhibitors

Global immune checkpoint inhibitors market reached $22 billion in 2019, quite a growth giving the fact that the first product in this new class of therapeutics was launched just 9 years ago and the market was valued at $360 million in 2011. The market took off in 2015, the first full year on the market of Keytruda and Opdivo, the two PD-1 inhibitors from Merck and Bristol-Myers Squibb, respectively. US is the largest market, accounting for 62% of global revenue, the country has the highest penetration and

Current Studies of Immunotherapy in Head and Neck Cancer

Current Studies of Immunotherapy in Head and Neck Cancer
  • Author : Anonim
  • Publisher : Unknown
  • Release : 10 April 2021
GET THIS BOOK Current Studies of Immunotherapy in Head and Neck Cancer

Abstract : Background: Recently, enormous progress in cancer therapy has been achieved by the use of immune checkpoint inhibitors. Activating the body's own immune system has added a novel and powerful therapeutic option for the treatment of melanoma and lung cancer. Furthermore, the potential use of immunotherapy is being extensively explored also in other malignancies. Objective of review: This review summarises current clinical studies using immune checkpoint modulators for the treatment of head and neck cancer (HNSCC). Type of review: Systematic

The Basics of Cancer Immunotherapy

The Basics of Cancer Immunotherapy
  • Author : Haidong Dong,Svetomir N. Markovic
  • Publisher : Springer
  • Release : 05 January 2018
GET THIS BOOK The Basics of Cancer Immunotherapy

This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize

Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development

Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development
  • Author : Nishant Khinduka Mehta
  • Publisher : Unknown
  • Release : 10 April 2021
GET THIS BOOK Investigation of VISTA as a Cancer Immune Checkpoint Via Structural Analysis and Therapeutic Antibody Development

Immunotherapy has shifted the landscape of cancer treatment with the advent of checkpoint inhibitors, which have become the standard of care for multiple types of cancer. Despite the remarkable success of anti-PD1 and anti-CTLA-4, patient response rates to checkpoint blockade are often only 20-30%, necessitating the need for new therapeutic targets. V-domain Ig Suppressor of T cell activation (VISTA) is an orthogonal checkpoint molecule that dampens the interaction between antigen-presenting cells and T cells to prevent effective anti-tumor responses. In